[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370752-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370752-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lncrna-nrad1-regulates-the-triple-negative-breast-cancer-transcriptome-by-mirna-biogenesis-localization-and-predominately-non-cerna-interactions","LncRNA NRAD1 regulates the triple-negative breast cancer transcriptome by miRNA biogenesis - localization - and predominately non-ceRNA interactions","","Triple-negative breast cancer (TNBC) is aggressive and lacks hormone receptor and HER2 targets, making chemotherapy central and creating major therapeutic challenges. Non-coding RNAs, especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), regulate gene expression and represent emerging targets. This study examines the TNBC-enriched lncRNA NRAD1 (formerly LINC00284), showing it is central to miRNA–mRNA networks and is primarily localized in nucleus and mitochondria.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lncrna-nrad1-regulates-the-triple-negative-breast-cancer-transcriptome-by-mirna-biogenesis-localization-and-predominately-non-cerna-interactions/370752/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lncrna-nrad1-regulates-the-triple-negative-breast-cancer-transcriptome-by-mirna-biogenesis-localization-and-predominately-non-cerna-interactions/370752.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is TNBC considered difficult to treat?","Question",{"text":63,"@type":64},"TNBC lacks hormone receptors and HER2, so receptor-targeting therapies are not applicable, leaving chemotherapy as the primary treatment and making disease progression more challenging.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does NRAD1 play in TNBC according to the study?",{"text":68,"@type":64},"NRAD1 is central to miRNA–mRNA networks in TNBC cells and promotes cancer-promoting gene expression changes.",{"name":70,"@type":61,"acceptedAnswer":71},"Where is NRAD1 primarily localized and what does that suggest?",{"text":72,"@type":64},"Fractionation studies indicate NRAD1 is mainly located in the nucleus and mitochondria, supporting transcript-specific interactions with miRNAs while enabling additional regulatory effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370752,1790217573,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLncRNA NRAD1 regulates the triple-negative breast cancer transcriptome by miRNAbiogenesis, localization, and predominately non-ceRNA interactions  \nHannah F. Cahill1, Justin M. Brown1, Manhattan Leslie-Toogood2,3, Jaganathan Venkatesh1,3, Marie-Claire D. Wasson1,3, Raj PranapArun1,3, Meghan E. McLean1, Dejan Vidovic4,5 & Paola Marcato1,2,3,5􀀍  \nBreast cancer is a leading cause of cancer mortality in women with triple-negative breast cancer (TNBC) presenting greater treatment challenges due to its aggressive disease progression. Understanding TNBC’s unique cell signaling and gene expression profiles will reveal novel therapeutic strategies. Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have emerged as key regulators of gene expression and potential therapeutic targets. This study focuses on aTNBC-enriched lncRNA, non-coding RNA in the aldehyde dehydrogenase 1A pathway (NRAD1, previously LINC00284), which promotes progression in multiple cancers. Our analysis reveals that NRAD1 is central to miRNA–mRNA networks inTNBC cells, mediating cancer-promoting gene expression changes. Fractionation studies showed that NRAD1 is primarily located in the nucleus and mitochondria, with some cytoplasmic presence allowing for transcript-specific competitive endogenous RNA (ceRNA) interactions with miRNAs. However, NRAD1 primarily effects miRNAs independently of ceRNA activity, instead upregulating DICER (a miRNA biogenesis protein), altering sub-cellular distribution, and reducing biogenesis of mitochondria-localized miRNA (i.e., miR-4485- 3p). These findings demonstrate novel regulatory interactions between the cancer-promoting lncRNANRAD1 and miRNAs that alter gene expression inTNBC, expanding our understanding of regulatory lncRNA–miRNA effects, TNBC biology, and highlighting future therapeutic strategies for targeting non-coding RNAs.  \nKeywords Long non-coding RNA, NRAD1, LINC00284, microRNA, Breast cancer, Triple-negative, Geneexpression  \nBreast cancer is the most diagnosed cancer in women and accounts for over 600,000 deaths globally per year1. Treatment regimens are largely based on the expression of three receptors, which define the three clinical breast cancer subtypes2. Hormone receptor positive (HR+) breast cancers express estrogen receptors (ER) and progesterone receptors (PR), and account for 70–75% of cases, and are treated with endocrine therapies, combined with chemotherapy in high-risk cases. Overexpression of the human epidermal growth factor receptor 2 (HER2) is present in 15–25% of breast cancers. Patients with HER2+ breast cancers are treated with HER2-targeting drugs in combination with chemotherapy. Triple-negative breast cancer (TNBC) lacks the three receptors, which prevents their treatment with these receptor-targeting drugs and makes chemotherapy the primary treatment.  \n1Department of Pathology, Dalhousie University, Rm 11C1, 5850 College Street, Halifax, NS B3H 4R2, Canada.  \n2Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada. 3Beatrice Hunter Cancer Research Institute, Dalhousie University, Halifax, NS, Canada. 4Department of Surgery, Dalhousie University, Halifax, NS, Canada. 5Nova Scotia Health Authority, Halifax, Canada. 􀀍 email: paola. marcato@dal.ca  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nIn addition to having different treatment regimens, the three major clinical breast cancer subtypes have distinct disease progression profiles, with TNBC being the most aggressive and likely to recur3. The subtypes present with distinct gene expression and cell signaling pathways4–6 Recent advancements in treatments for TNBCs by targeting genetic factors and molecular pathways associated with TNBC are improving outcomes (e.g., pembrolizumab and olaparib)7. This illustrates how understanding the unique cell signaling and gene expression pr","cbCait1P5UVJb4qk","https://ap.wps.com/l/cbCait1P5UVJb4qk","pdf",12914935,21,"English","# Background\n## TNBC treatment challenges\n## Non-coding RNAs as regulatory targets\n# Study focus and rationale\n## NRAD1 (LINC00284) in TNBC\n## miRNA biogenesis and localization mechanisms\n# Key findings (as described)\n## NRAD1-miRNA–mRNA network centrality\n## Predominantly non-ceRNA mode and DICER upregulation\n## Effects on mitochondria-localized miRNA biogenesis\n# Implications\n## Expanding lncRNA–miRNA regulatory understanding","[{\"question\":\"Why is TNBC considered difficult to treat?\",\"answer\":\"TNBC lacks hormone receptors and HER2, so receptor-targeting therapies are not applicable, leaving chemotherapy as the primary treatment and making disease progression more challenging.\"},{\"question\":\"What role does NRAD1 play in TNBC according to the study?\",\"answer\":\"NRAD1 is central to miRNA–mRNA networks in TNBC cells and promotes cancer-promoting gene expression changes.\"},{\"question\":\"Where is NRAD1 primarily localized and what does that suggest?\",\"answer\":\"Fractionation studies indicate NRAD1 is mainly located in the nucleus and mitochondria, supporting transcript-specific interactions with miRNAs while enabling additional regulatory effects.\"}]","LncRNA NRAD1 regulates the triple-negative breast cancer transcriptome by miRNA biogenesis - localization - and predominately non-ceRNA interactions | PDF",1790190218,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/426410cf583a376ba936186f7ae75ef8.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94ff57f24cfa4993f20ff42baac32743.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e129fe64e2f667df1bb0ef04f014a913.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4389a14ac990acd267545d75fc0a75d3.webp",980,1287]